GH Research PLC
NASDAQ:GHRS · NASDAQ Global Market
-$0.04 today
Vol 0.54M · Avg 0.23M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.3%
avg -21.9%
ROIC
-21.7%
avg -24.5%
ROA
-16.7%
avg -19.2%
Analysis
ROA is currently the strongest return metric at -16.7% versus its period average of -19.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Velichka Valcheva | Chief Executive Officer | — | — | 51 | $0.00 | <0.01% |
Aaron Cameron | Chief Operating Officer | — | — | 41 | $0.00 | <0.01% |
Florian Schonharting | Co-Founder & Non-Executive Chairman of the Board | — | — | 57 | $14.82M | 21.62% |
Magnus Halle | Co-Founder & MD of Ireland | — | — | 29 | $118,354.00 | 0.17% |
Julie Ryan | Vice President of Finance | — | — | 40 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Nanobiotix S.A.
NASDAQ:NBTX
$1.78B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.68B
Palvella Therapeutics, Inc.
NASDAQ:PVLA
$1.32B
Savara Inc.
NASDAQ:SVRA
$1.11B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$958.28M
Arbutus Biopharma Corporation
NASDAQ:ABUS
$883.98M
Kura Oncology, Inc.
NASDAQ:KURA
$853.03M
Rezolute, Inc.
NASDAQ:RZLT
$496.85M
ProKidney Corp.
NASDAQ:PROK
$262.25M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$189.54M
Who manages GHRS?
GH Research PLC (GHRS) lists 5 active executives. The top listed executive is Velichka Valcheva, Chief Executive Officer.
Are GHRS insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.